Emergent Biosolutions Inc Stock Price, News & Analysis

Emergent BioSolutions (NYSE: EBS) announced the FDA's approval to extend the shelf life of NARCAN® Nasal Spray from 24 to 36 months. This marks a significant improvement for this emergency opioid overdose treatment, which is the first FDA-approved nasal naloxone. Doug White, Senior VP, emphasized the extension as part of their ongoing innovation to meet healthcare needs.

In July, Emergent launched a new Generation II NARCAN® device that enhances storage conditions, making the product more accessible in emergencies.

Emergent BioSolutions (NYSE: EBS) announced that the FDA has extended the shelf life of NARCAN® Nasal Spray from 24 months to 36 months. This nasal spray is the first intranasal form of naloxone approved for emergency opioid overdose treatment. The company launched the Generation II NARCAN device in July, designed to enhance temperature stability. This extension reflects Emergent's commitment to improving product features for healthcare providers and first responders, addressing the critical needs in opioid overdose situations.

Emergent BioSolutions (NYSE:EBS) has completed a $450 million offering of 3.875% Senior Unsecured Notes due 2028. The offering aims to strengthen the company's financial position by repaying $353 million of its revolving credit facility. The remaining funds will support general corporate purposes. These Notes are guaranteed by all subsidiaries that hold debt under credit facilities. The offering is compliant with Rule 144A and Regulation S under the Securities Act, and it is important to note that the Notes are unregistered and subject to regulatory exemptions.

Emergent BioSolutions (NYSE:EBS) announced the pricing of its offering of $450 million in 3.875% Senior Unsecured Notes due 2028, increasing from an initial $400 million. The company plans to use $353 million of the proceeds to repay outstanding amounts under its revolving credit facility, with the remainder for general corporate purposes. The offering is set to close on August 7, 2020. The notes are guaranteed by the company’s subsidiaries and will be offered to qualified institutional buyers under Regulation S and Rule 144A of the Securities Act.

Emergent BioSolutions (EBS) reported significant growth in Q2 2020, achieving total revenues of $394.7 million, a 62.3% increase from $243.2 million in Q2 2019. The net income surged to $92.7 million, up from a loss of $9.5 million in the prior year. Key drivers include CDMO partnerships related to COVID-19, with a notable $628 million contract from HHS under Operation Warp Speed. Adjusted EBITDA reached $156.1 million, marking a 431% increase. The company revised its full-year revenue guidance upward to $1.5-$1.6 billion, highlighting continued operational strength despite pandemic challenges.

Emergent BioSolutions has secured a contract worth approximately $174 million with AstraZeneca for large-scale manufacturing of the COVID-19 vaccine candidate AZD1222. This agreement, valid through 2021, increases AstraZeneca's total commitment to $261 million. Emergent's Baltimore Bayview facility will handle production, leveraging its extensive capabilities for rapid vaccine manufacturing. As part of the U.S. government's Operation Warp Speed, Emergent aims to enhance public health efforts during the pandemic while preparing for potential future commitments in commercial manufacturing.

Emergent BioSolutions (NYSE: EBS) will join the S&P MidCap 400 index effective July 24, 2020. This milestone reflects the company's growth and commitment to public health. Richard S. Lindahl, CFO, stated that this addition signifies progress in maximizing shareholder value through revenue growth and reinvestment in the business. The S&P MidCap 400 serves as a benchmark for mid-sized companies, capturing their performance and unique market characteristics.

Emergent BioSolutions (NYSE: EBS) will hold a conference call on July 30, 2020, at 5:00 pm ET to discuss Q2 2020 financial results and provide revenue guidance for Q3 and the full year. The call can be accessed via telephone or webcast. Investors can view the live feed through the company’s website.

Emergent is focused on enhancing public health through innovative life sciences solutions, with a mission to protect 1 billion lives by 2030.

Emergent BioSolutions (NYSE: EBS) announced a $75 million investment to expand its Canton, Massachusetts facility, focusing on advanced therapy contract development and manufacturing (CDMO) services. This expansion aims to enhance capabilities in viral vector and gene therapy, with services expected to launch in 2023. The improved facility will enable molecule-to-market CDMO services integrating development, drug substance, and drug product manufacturing across its locations in Gaithersburg and Rockville, Maryland. This strategic move aligns with Emergent's growth plan and enhances its position in public health solutions.